Professor Craddock will take a lead role in developing high-quality research programmes in clinical and cost effectiveness research of cancer therapies and support the University’s work on Innovation particularly in the health theme including the development of the University’s supra-regional health innovation campus Arden Cross and other projects.

He trained in haematology at the Hammersmith Hospital in London, the Institute of Molecular Medicine at the University of Oxford, and the University of Washington in Seattle, USA. Professor Craddock is Chair of the UK Stem Cell Strategic Oversight Committee and was Medical Director of Anthony Nolan from 2010–2014. He was elected President of the British Society Of Haematology in 2017. He led the development of the £24 million Birmingham Institute of Translational Medicine, which opened in 2015 and in 2017 oversaw the £3.4m expansion of the Centre for Clinical Haematology at the Queen Elizabeth Hospital.

Professor Craddock’s main research interests include the development of novel drug and transplant therapies in myeloid leukaemia’s, and he leads the UK Haemato-oncology Trials Acceleration Programme. He pioneered the development of a UK stem cell transplant trials network, IMPACT, one of only two worldwide, which was launched in 2017.